1. Home
  2. WETH vs TPST Comparison

WETH vs TPST Comparison

Compare WETH & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

WETH

Wetouch Technology Inc.

HOLD

Current Price

$1.20

Market Cap

15.0M

Sector

N/A

ML Signal

HOLD

Logo Tempest Therapeutics Inc.

TPST

Tempest Therapeutics Inc.

HOLD

Current Price

$1.06

Market Cap

15.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WETH
TPST
Founded
1992
2011
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.0M
15.6M
IPO Year
2020
2012

Fundamental Metrics

Financial Performance
Metric
WETH
TPST
Price
$1.20
$1.06
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$11.00
AVG Volume (30 Days)
53.2K
230.5K
Earning Date
04-13-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
15.38
N/A
EPS
0.50
N/A
Revenue
$45,136,818.00
$295,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$2.40
N/A
Revenue Growth
6.76
N/A
52 Week Low
$0.92
$0.84
52 Week High
$3.68
$12.22

Technical Indicators

Market Signals
Indicator
WETH
TPST
Relative Strength Index (RSI) 50.74 49.76
Support Level $1.14 $1.02
Resistance Level $1.49 $1.09
Average True Range (ATR) 0.06 0.07
MACD 0.00 0.00
Stochastic Oscillator 45.45 32.35

Price Performance

Historical Comparison
WETH
TPST

About WETH Wetouch Technology Inc.

Wetouch Technology Inc is a business of research and development, manufacturing, and distribution of touchscreen displays to customers both in the PRC and overseas. The touchscreen products, which are manufactured by the Company, are mainly for use in financial terminals, automotive, Point of Sales, gaming, lottery, medical, Human-Machine Interface (HMI), and other specialized industries. The company sells touchscreen products both domestically in China and internationally, covering areas in Mainland China, including but not limited to the eastern, southern, northern, and southwest regions of Mainland China, Taiwan, South Korea, Germany, and other countries.

About TPST Tempest Therapeutics Inc.

Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.

Share on Social Networks: